Progress in research on recombinant vector vaccine against SARS-CoV-2

The global epidemic of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) poses a great threat to human life and health. At present, various types of vaccines have been approved for use worldwide to prevent the spread of the epidemic, among which recombinant vector vaccine plays an important role. Up to May 25, 2021, four vector vaccines have been approved for use in different countries, while 17 ones are in clinical trials and more than 40 ones in preclinical studies. This paper summarizes the research status of recombinant vector vaccine against SARS-CoV-2 in the world.